Research graph
References from CCNE1 : A Cell Cycle Regulator That Influences Tumor Progression. Local targets link to admitted publications; unresolved targets remain external evidence.
CCNE1 Amplification as a Predictive Biomarker of Chemotherapy Resistance in Epithelial Ovarian Cancer
10.3390/diagnostics10050279 · 2020 · External reference
Isolation of Three Novel Human Cyclins by Rescue of G1 Cyclin (Cln) Function in Yeast
10.1016/0092-8674(91)90042-w · 1991 · External reference
Regulation of Cyclin E Transcription by E2Fs and Retinoblastoma Protein
1996 · External reference
Down‐Regulation of CCNE1 Expression Suppresses Cell Proliferation and Sensitizes Gastric Carcinoma Cells to Cisplatin
10.1042/bsr20190381 · 2019 · External reference
Down‐Regulation of the Cyclin E1 Oncogene Expression by microRNA‐16‐1 Induces Cell Cycle Arrest in Human Cancer Cells
10.5483/bmbrep.2009.42.11.725 · 2009 · External reference
Long Non‐Coding RNA MCF2L‐AS1 Promotes the Aggressiveness of Colorectal Cancer by Sponging miR‐874‐3p and Thereby Up‐Regulating CCNE1
10.1002/jgm.3285 · 2021 · External reference
Knockdown of SENP1 Inhibits HIF‐1α SUMOylation and Suppresses Oncogenic CCNE1 in Wilms Tumor
10.1016/j.omto.2021.07.007 · 2021 · External reference
Clinical Characteristics and Outcomes of Phase I Cancer Patients With CCNE1 Amplification: MD Anderson Experiences
10.1038/s41598-022-12669-5 · 2022 · External reference
Expression Analysis With Oligonucleotide Microarrays Reveals That MYC Regulates Genes Involved in Growth, Cell Cycle, Signaling, and Adhesion
10.1073/pnas.97.7.3260 · 2000 · External reference
Correction: RAS/MAPK Activation Is Associated With Reduced Tumor‐Infiltrating Lymphocytes in Triple‐Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD‐1/PD‐L1 Immune Checkpoint Inhibitors
10.1158/1078-0432.ccr-18-4264 · 2019 · External reference
CCNE1 Amplification Is Associated With Poor Prognosis in Patients With Triple Negative Breast Cancer
10.1186/s12885-019-5290-4 · 2019 · External reference
CDK Inhibitors: Positive and Negative Regulators of G1‐Phase Progression
10.1101/gad.13.12.1501 · 1999 · External reference
CCNE1 Amplification Is Associated With Aggressive Potential in Endometrioid Endometrial Carcinomas
10.3892/ijo.2015.3268 · 2016 · External reference
Formation and Activation of a Cyclin E‐cdk2 Complex During the G1 Phase of the Human Cell Cycle
10.1126/science.1388288 · 1992 · External reference
Recycling the Cell Cycle: Cyclins Revisited
10.1016/s0092-8674(03)01080-8 · 2004 · External reference
Control of DNA Replication by Cyclin‐Dependent Kinases in Development
10.1007/978-3-642-19065-0_10 · 2011 · External reference
Distinct and Redundant Functions of Cyclin E1 and Cyclin E2 in Development and Cancer
10.1186/1747-1028-5-2 · 2010 · External reference
Ccne1 Overexpression Causes Chromosome Instability in Liver Cells and Liver Tumor Development in Mice
10.1053/j.gastro.2019.03.016 · 2019 · External reference
Motor Neuron and Pancreas Homeobox 1/HLXB9 Promotes Sustained Proliferation in Bladder Cancer by Upregulating CCNE1/2
10.1186/s13046-018-0829-9 · 2018 · External reference
CCNE1 Copy‐Number Gain and Overexpression Identify Ovarian Clear Cell Carcinoma With a Poor Prognosis
10.1038/modpathol.2016.160 · 2017 · External reference
Cyclin E Is a More Powerful Predictor of Breast Cancer Outcome Than Proliferation
10.1038/nm0203-152 · 2003 · External reference
Cyclin E Expression Is Correlated With Tumor Progression and Predicts a Poor Prognosis in Patients With Ovarian Carcinoma
10.1002/cncr.21767 · 2006 · External reference
Cyclin E1 (CCNE1) as Independent Positive Prognostic Factor in Advanced Stage Serous Ovarian Cancer Patients – A Study of the OVCAD Consortium
10.1016/j.ejca.2013.09.011 · 2014 · External reference
Combined CCNE1 High‐Level Amplification and Overexpression Is Associated With Unfavourable Outcome in Tubo‐Ovarian High‐Grade Serous Carcinoma
2020 · External reference
CCNE1 and Survival of Patients With Tubo‐Ovarian High‐Grade Serous Carcinoma: An Ovarian Tumor Tissue Analysis Consortium Study
10.1002/cncr.34582 · 2023 · External reference
Multiomic Analysis of CCNE1 Amplification Associated Molecular and Immune Features in Gynecological Cancers
10.1007/s12672-025-04032-7 · 2025 · External reference
Cyclin D1 Predicts the Prognosis of Advanced Serous Ovarian Cancer
10.3892/etm.2011.194 · 2011 · External reference
CCNE1 Promotes Progression and Is Associated With Poor Prognosis in Lung Adenocarcinoma
10.2174/1389201022666211118112935 · 2022 · External reference
Identification of the Prognostic and Therapeutic Values of Cyclin E1 (CCNE1) Gene Expression in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma: A Database Mining Approach
10.1016/j.heliyon.2022.e10367 · 2022 · External reference
CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2‐ Metastatic Breast Cancer
10.1158/1078-0432.ccr-22-2206 · 2023 · External reference
Upregulated Expression of BCL2, MCM7, and CCNE1 Indicate Cisplatin‐Resistance in the Set of Two Human Bladder Cancer Cell Lines: T24 Cisplatin Sensitive and T24R2 Cisplatin Resistant Bladder Cancer Cell Lines
10.4111/icu.2016.57.1.63 · 2016 · External reference
CCNE1 Copy Number Is a Biomarker for Response to Combination WEE1‐ATR Inhibition in Ovarian and Endometrial Cancer Models
10.1016/j.xcrm.2021.100394 · 2021 · External reference
CCNE1 Amplification Is Associated With Liver Metastasis in Gastric Carcinoma
10.1016/j.prp.2019.152434 · 2019 · External reference
Molecular Landscape and Clinical Implication of CCNE1‐Amplified Esophagogastric Cancer
10.1158/2767-9764.crc-23-0496 · 2024 · External reference
Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification
10.1200/jco.22.00830 · 2023 · External reference
Genomic Instability—An Evolving Hallmark of Cancer
10.1038/nrm2858 · 2010 · External reference
CCNE1 Amplification as a Therapeutic Target
10.1200/jco.22.02267 · 2023 · External reference
CDK2 Regulates Collapsed Replication Fork Repair in CCNE1‐Amplified Ovarian Cancer Cells via Homologous Recombination
10.1093/narcan/zcad039 · 2023 · External reference
CCNE1 Amplification Is Synthetic Lethal With PKMYT1 Kinase Inhibition
10.1038/s41586-022-04638-9 · 2022 · External reference
Clinical Significance of CCNE1 Copy Number Gain in Acral Melanoma Patients
10.1097/cmr.0000000000000742 · 2021 · External reference
CCNE1 Is a Potential Target of Metformin for Tumor Suppression of Ovarian High‐Grade Serous Carcinoma
10.1080/15384101.2022.2109362 · 2023 · External reference
Adavosertib Is Safe and Efficacious in CCNE1‐Amplified Solid Tumors
10.1158/2159-8290.cd-rw2022-220 · 2023 · External reference
Overexpression of Cyclin E1 or Cdc25A Leads to Replication Stress, Mitotic Aberrancies, and Increased Sensitivity to Replication Checkpoint Inhibitors
10.1038/s41389-020-00270-2 · 2020 · External reference
Cyclin E Expression Is Associated With High Levels of Replication Stress in Triple‐Negative Breast Cancer
10.1038/s41523-020-00181-w · 2020 · External reference
WEE1i‐ATRi Combination Therapy: A Promising Low‐Dose Treatment for CCNE1‐Amplified Gynecologic Cancers
10.1016/j.xcrm.2021.100402 · 2021 · External reference
'brcaness' and Its Implications for Platinum Action in Gynecologic Cancer
2014 · External reference
CHK1 Inhibitor SRA737 Is Active in PARP Inhibitor Resistant and CCNE1 Amplified Ovarian Cancer
10.1016/j.isci.2024.109978 · 2024 · External reference
Characterization of the 19q12 Amplification Including CCNE1 and URI in Different Epithelial Ovarian Cancer Subtypes
10.1016/j.yexmp.2014.12.004 · 2015 · External reference
Targeting Therapeutic Resistance and Multinucleate Giant Cells in CCNE1‐Amplified HR‐Proficient Ovarian Cancer
10.1158/1535-7163.mct-21-0873 · 2022 · External reference
Synthetic Lethality Between CCNE1 Amplification and Loss of BRCA1
10.1073/pnas.1314302110 · 2013 · External reference
CCNE1 Is a Putative Therapeutic Target for ARID1A‐Mutated Ovarian Clear Cell Carcinoma
10.3390/ijms22115869 · 2021 · External reference
Rb1 Deficiency Induces Synthetic Lethality With ATR and PKMYT1 Coinhibition in Breast Cancer Cell Lines and Patient‐Derived Xenografts
10.1126/scitranslmed.adx6797 · 2025 · External reference
Targeting CCNE1 Amplified Ovarian and Endometrial Cancers by Combined Inhibition of PKMYT1 and ATR
10.1038/s41467-025-58183-w · 2025 · External reference
ATR and PKMYT1 Inhibition Resensitizes a Subset of TNBC Patient‐Derived Models to Carboplatin, Inducing Mitotic Catastrophe
10.1158/2767-9764.crc-25-0044 · 2026 · External reference
CCNE1 and BRD4 Co‐Amplification in High‐Grade Serous Ovarian Cancer Is Associated With Poor Clinical Outcomes
10.1016/j.ygyno.2020.01.038 · 2020 · External reference
Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer
10.1158/2159-8290.cd-20-0455 · 2021 · External reference
Cyclin E1 in Murine and Human Liver Cancer: A Promising Target for Therapeutic Intervention During Tumour Progression
10.3390/cancers13225680 · 2021 · External reference
10.64898/2025.12.17.694745
10.64898/2025.12.17.694745 · External reference
Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once‐Daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients With Advanced Solid Tumors
10.1158/1078-0432.ccr-21-0329 · 2021 · External reference
Long Non‐Coding RNA SENP3‐EIF4A1 Functions as a Sponge of miR‐195‐5p to Drive Triple‐Negative Breast Cancer Progress by Overexpressing CCNE1
10.3389/fcell.2021.647527 · 2021 · External reference
MicroRNAs: Small RNAs With a Big Role in Gene Regulation
10.1038/nrg1379 · 2004 · External reference
miR‐497/MIR497HG Inhibits Glioma Cell Proliferation by Targeting CCNE1 and the miR‐588/TUSC1 Axis
10.3892/or.2021.8206 · 2021 · External reference
Tumour‐Suppressive microRNA‐424‐5p Directly Targets CCNE1 as Potential Prognostic Markers in Epithelial Ovarian Cancer
10.1080/15384101.2017.1407894 · 2018 · External reference
Ectopic Expression of microRNA‐874 Represses Epithelial Mesenchymal Transition Through the NF‐κB Pathway via CCNE1 in Cholangiocarcinoma
10.1016/j.cellsig.2021.109927 · 2021 · External reference
hsa_circ_0062389 Promotes the Progression of Non‐Small Cell Lung Cancer by Sponging miR‐103a‐3p to Mediate CCNE1 Expression
10.1016/j.cancergen.2019.12.004 · 2020 · External reference
CircROR1 Upregulates CCNE1 Expression to Promote Melanoma Invasion and Metastasis by Recruiting KAT2A
10.1111/exd.15071 · 2024 · External reference
MEG3 LncRNA From Exosomes Released From Cancer‐Associated Fibroblasts Enhances Cisplatin Chemoresistance in SCLC via a MiR‐15a‐5p/CCNE1 Axis
10.3349/ymj.2022.63.3.229 · 2022 · External reference
LncRNA OXCT1‐AS1 Promotes the Proliferation of Non‐Small Cell Lung Cancer Cells by Targeting the miR‐195/CCNE1 Axis
10.21037/tcr-22-855 · 2022 · External reference
HOXC13 Promotes Proliferation of Lung Adenocarcinoma via Modulation of CCND1 and CCNE1
2017 · External reference
Circular RNA circSEMA5A Facilitates Colorectal Cancer Development by Regulating microRNA‐195‐5p to Target CCNE1 Axis
10.1016/j.cellsig.2023.110649 · 2023 · External reference
MiR‐15b Regulates Cell Differentiation and Survival by Targeting CCNE1 in APL Cell Lines
10.1016/j.cellsig.2019.04.005 · 2019 · External reference
MicroRNA‐7 Arrests Cell Cycle in G1 Phase by Directly Targeting CCNE1 in Human Hepatocellular Carcinoma Cells
10.1016/j.bbrc.2013.12.095 · 2014 · External reference
E6 Hijacks KDM5C/lnc_000231/miR‐497‐5p/CCNE1 Axis to Promote Cervical Cancer Progression
10.1111/jcmm.15746 · 2020 · External reference
CircDENND2A Promotes Non‐Small Cell Lung Cancer Progression via Regulating MiR‐34a/CCNE1 Signaling
10.3389/fgene.2020.00987 · 2020 · External reference
Silencing of Long Noncoding RNA MYLK‐AS1 Suppresses Nephroblastoma via Down‐Regulation of CCNE1 Through Transcription Factor TCF7L2
10.1002/jcp.30259 · 2021 · External reference
MicroRNA miR‐16‐1 Regulates CCNE1 (Cyclin E1) Gene Expression in Human Cervical Cancer Cells
2015 · External reference
KDM5B Promotes Tumorigenesis of Ewing Sarcoma via FBXW7/CCNE1 Axis
10.1038/s41419-022-04800-1 · 2022 · External reference
AURKB Promotes Colorectal Cancer Progression by Triggering the Phosphorylation of Histone H3 at Serine 10 to Activate CCNE1 Expression
2024 · External reference
SCUBE3 Downregulation Modulates Hepatocellular Carcinoma by Inhibiting CCNE1 via TGFβ/PI3K/AKT/GSK3β Pathway
10.1186/s12935-021-02402-z · 2022 · External reference
CCNE1 Is a Predictive and Immunotherapeutic Indicator in Various Cancers Including UCEC: A Pan‐Cancer Analysis
10.1186/s41065-023-00273-0 · 2023 · External reference
Methyltransferase Like 3 Promotes Colorectal Cancer Proliferation by Stabilizing CCNE1 mRNA in an m6A‐Dependent Manner
10.1111/jcmm.15042 · 2020 · External reference
CCNE1 and E2F1 Partially Suppress G1 Phase Arrest Caused by Spliceostatin A Treatment
10.3390/ijms222111623 · 2021 · External reference
Discovery of a Novel 1H‐Pyrazole‐ [3,4‐b] Pyridine‐Based Lysine Demethylase 5B Inhibitor With Potential Anti‐Prostate Cancer Activity That Perturbs the Phosphoinositide 3‐Kinase/AKT Pathway
10.1016/j.ejmech.2023.115250 · 2023 · External reference
Design, Synthesis, and Biological Evaluation of KDM5B Degraders Against Hematologic Malignancy Cells
10.1016/j.ejmech.2025.117883 · 2025 · External reference
Identification of Novel Small‐Molecule Inhibitors Targeting KDM5B and Evaluation of Their Antitumour Effects
10.1002/cam4.72058 · 2026 · External reference
Naturally Derived SENP1 Inhibitors With Anticancer Activity
10.3390/ijms262211210 · 2025 · External reference
Antibody‐Mediated Targeting of Secretory Protein SCUBE3 Suppresses Cancer Progression by Inhibiting Oncogenic Signaling and Inducing Antitumor Immunity
10.1158/0008-5472.can-25-0521 · 2026 · External reference
Reduction of SCUBE3 by a New Marine‐Derived Asterosaponin Leads to Arrest of Glioma Cells in G1/S
10.1038/s41389-020-00252-4 · 2020 · External reference
A PROTAC Targets Splicing Factor 3B1
10.1016/j.chembiol.2021.04.018 · 2021 · External reference
Phase I First‐In‐Human Dose Escalation Study of the Oral SF3B1 Modulator H3B‐8800 in Myeloid Neoplasms
10.1038/s41375-021-01328-9 · 2021 · External reference
